Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;26(6):e14371.
doi: 10.1111/tid.14371. Epub 2024 Sep 3.

Early clearance of BK polyomavirus-DNAemia among kidney transplant recipients may lead to better graft survival

Affiliations

Early clearance of BK polyomavirus-DNAemia among kidney transplant recipients may lead to better graft survival

Isabel Breyer et al. Transpl Infect Dis. 2024 Dec.

Abstract

Introduction: BK polyomavirus (BKPyV)-DNAemia is a common complication in kidney transplant recipients (KTRs). The significance of achieving viral clearance at different time intervals is not well understood.

Methods: All adult KTRs transplanted between January 1, 2015 and December 31, 2017 who developed BKPyV-DNAemia were included. Outcomes were analyzed based on persistent clearance of BKPyV-DNAemia at 3-month intervals up to 2 years after initial detection, and for recipients with persistent BKPyV-DNAemia at last follow-up. Uncensored graft failure, death-censored graft failure (DCGF), and a composite outcome of DCGF or fall in estimated glomerular filtration rate (eGFR) by ≥50% from the time of initial BKPyV-DNAemia were outcomes of interest.

Results: Of 224 KTRs with BKPyV-DNAemia, 58 recipients (26%) achieved viral clearance by 3 months after initial detection, 105 (47%) by 6 months, 120 (54%) by 9 months, 141 (63%) by 12 months, 155 (69%) by 15 months, 167 (75%) by 18 months, 180 (80%) by 21 months, and 193 (86%) by 24 months. Nine recipients (4%) had persistent BKPyV-DNAemia at last follow-up. Compared to recipients who achieved viral clearance by 3 months, those who achieved clearance by 6 months (adjusted odds ratio [aOR]: 3.15; 95% confidence interval [CI]: 1.22-8.12; p = .02) and 9 months (aOR: 3.69; 95% CI: 1.02-13.43; p = .04) had significantly increased risk for uncensored graft failure. There was no significant association between time to viral clearance and DCGF or composite outcomes.

Conclusions: We found a trend of increased risk for uncensored graft failure among those who cleared BKPyV-DNAemia more slowly. Aiming to clear viremia early, without risking rejection, may be beneficial for allograft function and patient morbidity and mortality.

Keywords: BK viremia; clearance; graft failure; outcomes.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Outcomes of interest based on BK polyomavirus (BKPyV)‐DNAemia clearance at various time frames.
FIGURE 2
FIGURE 2
Outcomes of interest based on BK polyomavirus (BKPyV)‐DNAemia clearance by 3 months versus beyond 3 months. eGFR, estimated glomerular filtration rate.

References

    1. Hirsch HH, Randhawa PS, Practice AIDCo . BK polyomavirus in solid organ transplantation—guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13528. - PubMed
    1. Hassan S, Mittal C, Amer S, et al. Currently recommended BK virus (BKV) plasma viral load cutoff of ≥4 log10/mL underestimates the diagnosis of BKV‐associated nephropathy: a single transplant center experience. Transpl Infect Dis. 2014;16(1):55‐60. - PubMed
    1. Kant S, Dasgupta A, Bagnasco S, Brennan DC. BK virus nephropathy in kidney transplantation: a state‐of‐the‐art review. Viruses. 2022;14(8):1616. - PMC - PubMed
    1. Basse G, Mengelle C, Kamar N, et al. Prospective evaluation of BK virus DNAemia in renal transplant patients and their transplant outcome. Transplant Proc. 2007;39(1):84‐87. - PubMed
    1. Cotiguala L, Masood A, Park JM, et al. Increasing net immunosuppression after BK polyoma virus infection. Transpl Infect Dis. 2021;23(2):e13472. - PubMed